Bessemer Group
MRNA icon

Bessemer Group’s Moderna MRNA Stock Holding History

Bessemer Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371K Buy
5,305
+286
+6% +$14.8K ﹤0.01% 1252
2026
Q1 		$255K Buy
5,019
+1,097
+28% +$51.2K ﹤0.01% 1333
2025
Q4 		$116K Sell
3,922
-260
-6% -$7.06K ﹤0.01% 1459
2025
Q3 		$109K Sell
4,182
-3,767
-47% -$105K ﹤0.01% 1256
2025
Q2 		$219K Sell
7,949
-3,655
-31% -$96.3K ﹤0.01% 1072
2025
Q1 		$329K Buy
11,604
+6,642
+134% +$236K ﹤0.01% 970
2024
Q4 		$206K Sell
4,962
-658
-12% -$31.4K ﹤0.01% 1065
2024
Q3 		$376K Sell
5,620
-2,324
-29% -$213K ﹤0.01% 967
2024
Q2 		$943K Buy
7,944
+686
+9% +$86.8K ﹤0.01% 669
2024
Q1 		$774K Buy
7,258
+276
+4% +$27.8K ﹤0.01% 713
2023
Q4 		$694K Buy
6,982
+1,065
+18% +$89.6K ﹤0.01% 735
2023
Q3 		$611K Sell
5,917
-5,553
-48% -$619K ﹤0.01% 745
2023
Q2 		$1.39M Buy
11,470
+4,202
+58% +$561K ﹤0.01% 564
2023
Q1 		$1.12M Sell
7,268
-323
-4% -$53.3K ﹤0.01% 563
2022
Q4 		$1.36M Buy
7,591
+1,210
+19% +$198K ﹤0.01% 524
2022
Q3 		$755K Sell
6,381
-1,081
-14% -$164K ﹤0.01% 639
2022
Q2 		$1.07M Buy
7,462
+4,276
+134% +$611K ﹤0.01% 562
2022
Q1 		$548K Buy
3,186
+932
+41% +$157K ﹤0.01% 618
2021
Q4 		$573K Sell
2,254
-97
-4% -$28.4K ﹤0.01% 603
2021
Q3 		$905K Buy
2,351
+2,251
+2,251% +$830K ﹤0.01% 435
2021
Q2 		$24K Buy
+100
New +$17.9K ﹤0.01% 1203
2020
Q4 		– Sell
-60
Closed -$4K – 1519
2020
Q3 		$4K Sell
60
-360
-86% -$25.1K ﹤0.01% 1215
2020
Q2 		$27K Buy
+420
New +$23K ﹤0.01% 1421

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Bessemer Group's MRNA Position: Q2 2026 in Review

Bessemer Group increased its Moderna (MRNA) stake by 5.7% in Q2 2026, buying an estimated $14.8K and bringing the position to 5,305 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #1252.

Bessemer Group first reported a position in MRNA in Q2 2020 and has held it in 23 quarters since. The position peaked at $1.39M in Q2 2023. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Bessemer Group held 5,305 shares of Moderna worth $371K as of Q2 2026.
  • Bessemer Group bought 286 Moderna shares in Q2 2026, an estimated $14.8K.
  • Moderna made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1252 holding.
  • Bessemer Group first reported a position in Moderna in Q2 2020 and has held it in 23 quarters since.
  • Bessemer Group's Moderna position peaked at $1.39M in Q2 2023.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.